New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapyResults from an interim analysis featured in late-breaker oral presentation at WCLCSAN DIEGO, Sept. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced longer follow-up data from the landmark Phase 3 MARIPOSA study which showed first-line treatment with RYBREVANT® (amivantamab-vmjw) combined with LAZCLUZE™ (la ...

Johnson & Johnson (NYSE:JNJ) Wells Fargo 2024 Healthcare Conference September 5, 2024 11:00 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech Jessica Moore - Vice President of Investor Relations Tracy Menkowski - Senior Director of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Barry, we're ready? All right, good morning. Welcome back. I am Larry Biegelsen, the Medical Device Analyst at Wells Fargo. And it's my plea ...

Johnson & Johnson (NYSE:JNJ) Wells Fargo 2024 Healthcare Conference September 5, 2024 11:00 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech Jessica Moore - Vice President of Investor Relations Tracy Menkowski - Senior Director of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Barry, we're ready? All right, good morning. Welcome back. I am Larry Biegelsen, the Medical Device Analyst at Wells Fargo. And it's my plea ...

Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.Investing in dividend stocks can seem like a great way to pad your portfolio's returns, especially when you're investing in dividend growth stocks that increase their payments over the years. The risk, however, is that investors often look at a stock's track record for paying dividends, and use that as a justification for why it may be a safe income investment to hold for the long term. But the past do ...

Johnson & Johnson (NYSE:JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 10:45 AM ET Company Participants Joaquin Duato - CEO & Chairman John Reed - Head of Pharma R&D Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. All right. Thanks for joining us, everybody. I'm Terence Flynn, the U.S. large cap biopharma analyst. Very pleased to be hosting Johnson & Johnson this morning. For important disclosures, please see the Morgan Stanley Research discl ...

Company and Industry Overview * **Company**: Johnson & Johnson (NYSE: JNJ) * **Industry**: Healthcare, Pharmaceuticals, Medical Technology Key Points Growth Targets and Confidence * **2025 Revenue Growth**: Johnson & Johnson aims for more than 3% revenue growth in 2025, with a focus on Innovative Medicine Group (IMG) growing 5% to 7% from 2025 to 2030. * **Confidence Source**: The company's strong performance in 2024, with total revenue growth of over 7% and EPS growth of 11%. * **Growth Drivers**: * **Innovative Medicine**: Multiple myeloma, prostate cancer, neuroscience, and pulmonary arterial hypertension franchises. * **MedTech**: Vision franchise (ACUVUE OASYS MAX), cardiovascular (PFA catheters, Impella, Shockwave), and orthopedic (VELYS robotics, OTTAVA robotic system). * **Regulatory Milestones and Data Readouts**: Nipocalimab in myasthenia gravis, TARIS in non-muscle invasive bladder cancer, oral IL-23 in psoriasis and IBD, and RYBREVANT plus LAZCLUZE in EGFR mutated NSCLC. Mergers and Acquisitions (M&A) * **Focus**: Growth MedTech assets and early-stage deals in innovative medicine. * **Investment**: Approximately $18 billion in M&A in the first half of 2024, including acquisitions of Shockwave, V-Wave, Ambrx, Proteologics, and yellow jacketing bispecific antibodies. * **Criteria**: Strategic, scientific, and financial considerations. IRA Medicare Part D Negotiations * **Impact**: Negative impact on innovation and R&D investment. * **Adaptation**: * Multiple parallel indication seeking. * Development of subcutaneous formulations for biologics. * Focus on first-in-class and best-in-class medicines. Pipeline Assets * **Oral IL-23 Inhibitor**: Phase II data in psoriasis showed impressive efficacy, with PASI 75 data around 70% and PASI 100 data around 40%. * **TREMFYA**: Phase II data in IBD showed high levels of endoscopy complete remission, with approximately 1/3 of patients showing no evidence of disease after one year. * **TAR-200**: Med device combo for bladder cancer, with unprecedented rates of complete response and breakthrough designation from the FDA. * **RYBREVANT-lazertinib**: Combination therapy for EGFR mutated NSCLC, with promising data in progression-free survival and overall survival. Other Important Points * **Obesity**: Interest in exploring differentiated assets in obesity, particularly those targeting hunger and satiation in the brain. * **Talc Litigation**: Prepackaged bankruptcy for ovarian cancer claims, with confidence in achieving the required 75% voting threshold. * **Market Positioning**: The oral IL-23 inhibitor is positioned as a treatment option for patients who do not want to use injectables or are not candidates for advanced therapies.

Johnson & Johnson (JNJ) submitted abiologics license application (BLA) to the FDA seeking approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized myasthenia gravis (gMG) indication.The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with gMG, including those with anti-AChR, anti-MuSK and anti-LRP4 positive antibodies. Data from the study showed that patients who received nipocalimab plus standard of care ( ...

In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts. Notably, some stocks are set up to reward shareholders regularly. As the markets look ahead to 2025, several stocks can be tapped to offer passive income. Some of these companies have a history of stable dividends and consistent growth.Therefore, below are three stocks to consider for a dividend-focused portfolio in 2025. Johnson & Johnson (NYSE: JNJ ...

CHINA - 2024/07/27: In this photo illustration, Johnson & Johnson logo is displayed on a smartphone ... [+] with a laptop keyboard background. (Photo Illustration by Serene Lee/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIf you are a Johnson & Johnson investor and have been enjoying the stock’s steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric an ...

Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross. This technical pattern occurs when a stock’s short-term moving average crosses above its long-term moving average, indicating a potential shift from a bearish to a bullish trend. Chart created using Benzinga ProFor Johnson & Johnson, the stock’s 50-day simple moving average (SMA) of $155.36 has crossed above the 200-day SMA of $154.46, signaling strong upward momentum.Golden Cross: What It Means For Johnson & Johnson ...